Deregulation of AKT (protein kinase B) is frequently observed in human malignancies including gastrointestinal (GI) cancers. Here we have reviewed the association between AKT phosphorylation (activation) and clinical and pathological characteristics of patients with GI cancer. Articles in the EMBASE, PubMed, Cochrane Library, and Web of Science databases were searched up to July 2018. Eighteen studies comprising 1,698 patients with 5 different cancer types were included in the meta-analysis. In the pooled analysis, AKT phosphorylation was positively correlated with tumor size (r = 0.14, 95% CI: 0.06-0.22; P < 0.001), tumor grade (r = 0.08, 95% CI: 0.02-0.14; P < 0.009), tumor stage (r = 0.19, 95% CI: 0.13-0.24; P < 0.001), lymph node status (r = 0.18, 95% CI: 0.09-0.25; P < 0.001) and the presence of distant metastasis (r = 0.14, 95% CI: 0.06-0.22; P < 0.001) in the patients with GI cancer. These findings support the potential clinical value of AKT as a prognostic marker and therapeutic target in patients with GI carcinomas.

中文翻译：

---

磷酸化AKT表达与胃肠道癌患者临床病理特征的临床关联：一项荟萃分析。

在包括胃肠道（GI）癌在内的人类恶性肿瘤中经常观察到AKT（蛋白激酶B）的失调。在这里，我们已经审查了AKT磷酸化（激活）与胃肠道癌患者的临床和病理特征之间的关联。截至2018年7月，对EMBASE，PubMed，Cochrane图书馆和Web of Science数据库中的文章进行了搜索。荟萃分析包括18项研究，包括1698名患有5种不同癌症类型的患者。在汇总分析中，AKT磷酸化与肿瘤大小呈正相关（r = 0.14，95％CI：0.06-0.22; P <0.001），肿瘤等级（r = 0.08，95％CI：0.02-0.14; P <0.009） ，肿瘤分期（r = 0.19，95％CI：0.13-0.24; P<0.001），患者的淋巴结状况（r = 0.18，95％CI：0.09-0.25; P <0.001）和远处转移的存在（r = 0.14，95 ％CI：0.06-0.22; P <0.001）胃肠道癌。这些发现支持了AKT在GI癌患者中作为预后标志物和治疗靶标的潜在临床价值。